Witnessing the stock’s movement on the chart, on Thursday, Cytokinetics Inc (NASDAQ: CYTK) had a quiet start as it plunged -6.11% to $58.96, before settling in for the price of $62.8 at the close. Taking a more long-term approach, CYTK posted a 52-week range of $29.31-$63.86.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -20.02%. Meanwhile, its Annual Earning per share during the time was -20.02%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -6.85%. This publicly-traded company’s shares outstanding now amounts to $119.60 million, simultaneously with a float of $117.04 million. The organization now has a market capitalization sitting at $7.05 billion. At the time of writing, stock’s 50-day Moving Average stood at $48.00, while the 200-day Moving Average is $41.79.
Cytokinetics Inc (CYTK) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Cytokinetics Inc’s current insider ownership accounts for 2.19%, in contrast to 114.19% institutional ownership. According to the most recent insider trade that took place on Oct 16 ’25, this organization’s President & CEO sold 5,000 shares at the rate of 60.03, making the entire transaction reach 300,150 in total value, affecting insider ownership by 363,108. Preceding that transaction, on Oct 07 ’25, Company’s EVP Research & Development sold 2,000 for 60.56, making the whole transaction’s value amount to 121,120. This particular insider is now the holder of 140,610 in total.
Cytokinetics Inc (CYTK) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.57 per share during the current fiscal year.
Cytokinetics Inc’s EPS decrease for this current 12-month fiscal period is -6.85% and is forecasted to reach -5.68 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 11.62% through the next 5 years, which can be compared against the -20.02% growth it accomplished over the previous five years trading on the market.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
Let’s observe the current performance indicators for Cytokinetics Inc (CYTK). It’s Quick Ratio in the last reported quarter now stands at 6.76. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 82.28.
In the same vein, CYTK’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -5.12, a figure that is expected to reach -1.57 in the next quarter, and analysts are predicting that it will be -5.68 at the market close of one year from today.
Technical Analysis of Cytokinetics Inc (CYTK)
Going through the that latest performance of [Cytokinetics Inc, CYTK]. Its last 5-days volume of 1.81 million was inferior to the volume of 1.93 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 67.68% While, its Average True Range was 56.78.
Raw Stochastic average of Cytokinetics Inc (CYTK) in the period of the previous 100 days is set at 85.61%, which indicates a major rise in contrast to 64.26% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 2.65 that was higher than 1.82 volatility it exhibited in the past 100-days period.
